{"id":64705,"date":"2026-05-08T14:14:35","date_gmt":"2026-05-08T06:14:35","guid":{"rendered":"https:\/\/flcube.com\/?p=64705"},"modified":"2026-05-08T14:14:36","modified_gmt":"2026-05-08T06:14:36","slug":"suzhou-zelgen-biopharmaceuticals-achieves-primary-endpoint-in-phase-iii-trial-for-zesuning-in-thyroid-cancer-ablation-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64705","title":{"rendered":"Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy"},"content":{"rendered":"\n<p><strong>Suzhou Zelgen Biopharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688266:SHA\">SHA: 688266<\/a>) announced that its <strong>Phase III clinical trial<\/strong> of <strong>Zesuning (recombinant human thyrotropin \u03b2)<\/strong> has met the <strong>prespecified primary endpoint<\/strong> for <strong>postoperative radioactive iodine remnant ablation<\/strong> in patients with <strong>differentiated thyroid carcinoma (DTC)<\/strong>. The positive results support a planned <strong>new indication submission<\/strong> to China&#8217;s <strong>Center for Drug Evaluation (CDE)<\/strong>, expanding beyond Zesuning&#8217;s current approved use as a diagnostic adjunct.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-milestone\">Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Name<\/strong><\/td><td>Zesuning (recombinant human thyrotropin \u03b2, rhTSH)<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Therapeutic biological product (Class 1 biologic)<\/td><\/tr><tr><td><strong>Current Indication<\/strong><\/td><td>Adjunctive diagnostic tool for serum thyroglobulin testing \u00b1 radioactive iodine whole-body scan (approved January 2026)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Postoperative radioactive iodine remnant ablation in DTC patients<\/td><\/tr><tr><td><strong>Trial Status<\/strong><\/td><td>Phase III primary endpoint met; full data analysis ongoing<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Market authorization application to CDE\/NMPA for expanded indication<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-biological-profile\">Mechanism of Action &amp; Biological Profile<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-molecular-characteristics\">Molecular Characteristics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Structure<\/strong>: Recombinant human thyrotropin beta (rhTSH) with <strong>identical amino acid sequence<\/strong> to natural human TSH<\/li>\n\n\n\n<li><strong>Target<\/strong>: Human thyroid-stimulating hormone receptor (hTSHR) expressed on thyroid cells and well-differentiated thyroid cancer cells<\/li>\n\n\n\n<li><strong>Biological Function<\/strong>: Stimulates <strong>iodine uptake and organification<\/strong>, plus synthesis and release of <strong>thyroglobulin (Tg)<\/strong>, <strong>triiodothyronine (T3)<\/strong>, and <strong>thyroxine (T4)<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-therapeutic-applications\">Therapeutic Applications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Diagnostic Use<\/strong>: rhTSH activation induces thyroid cells to release <strong>thyroglobulin<\/strong>, serving as a <strong>detectable tumor marker<\/strong> in blood samples for cancer monitoring<\/li>\n\n\n\n<li><strong>Therapeutic Use<\/strong>: Enhanced <strong>radioactive iodine uptake<\/strong> enables more effective ablation of residual thyroid tissue and cancer cells post-surgery<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-timeline-amp-commercial-strategy\">Regulatory Timeline &amp; Commercial Strategy<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-current-approval-status\">Current Approval Status<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>January 2026<\/strong>: NMPA approval for <strong>diagnostic indication<\/strong> in DTC patients following total\/near-total thyroidectomy<\/li>\n\n\n\n<li><strong>Current Submission<\/strong>: Diagnostic use for <strong>serum thyroglobulin testing<\/strong> with or without <strong>\u00b9\u00b3\u00b9I whole-body scan (WBS)<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-expanded-indication-pathway\">Expanded Indication Pathway<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase III Success<\/strong>: Primary endpoint achievement validates therapeutic efficacy for <strong>remnant ablation<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Filing<\/strong>: Planned submission to CDE for <strong>therapeutic indication<\/strong> expansion<\/li>\n\n\n\n<li><strong>Market Differentiation<\/strong>: Potential to become <strong>first domestically developed rhTSH<\/strong> approved for both diagnostic and therapeutic uses in China<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-assessment\">Market Opportunity Assessment<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Thyroid Cancer Burden<\/strong>: China reports <strong>over 200,000 new thyroid cancer cases annually<\/strong>, with <strong>differentiated thyroid carcinoma<\/strong> representing <strong>90\u201395%<\/strong> of cases<\/li>\n\n\n\n<li><strong>Current Treatment Gap<\/strong>: Limited domestic options for rhTSH therapy; market currently served by imported products at premium pricing<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: Zesuning would compete with <strong>Genzyme&#8217;s Thyrogen<\/strong> (sanofi), the global standard for rhTSH therapy<\/li>\n\n\n\n<li><strong>Pricing Advantage<\/strong>: Domestic production expected to reduce treatment costs by <strong>30\u201350%<\/strong> compared to imported alternatives<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-and-strategic-implications\">Investment and Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Stock Performance<\/strong>: SHA: 688266 closed at \u00a542.18 on May 7, 2026; biotech sector showing strong momentum in Q2 2026<\/li>\n\n\n\n<li><strong>Pipeline Valuation<\/strong>: Zesuning represents Zelgen&#8217;s <strong>flagship commercial asset<\/strong>; dual indication approval could generate <strong>\u00a5500\u2013800 million<\/strong> ($70\u2013110 million) in peak annual revenue<\/li>\n\n\n\n<li><strong>Reimbursement Strategy<\/strong>: Target inclusion in <strong>National Reimbursement Drug List (NRDL)<\/strong> for both diagnostic and therapeutic indications<\/li>\n\n\n\n<li><strong>Manufacturing Readiness<\/strong>: Existing GMP facilities capable of supporting commercial-scale production upon approval<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial outcomes, regulatory submissions, and commercial projections for Zesuning. Actual results may vary due to regulatory review timelines, competitive dynamics, and market access negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688266_20260508_3C2O.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688266_20260508_3C2O.\"><\/object><a id=\"wp-block-file--media-48878716-8073-4fde-bb8e-b6f90593ca17\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688266_20260508_3C2O.pdf\">688266_20260508_3C2O<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688266_20260508_3C2O.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-48878716-8073-4fde-bb8e-b6f90593ca17\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its Phase III clinical trial of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,905,246],"class_list":["post-64705","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-sha-688266","tag-zelgen-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its Phase III clinical trial of Zesuning (recombinant human thyrotropin \u03b2) has met the prespecified primary endpoint for postoperative radioactive iodine remnant ablation in patients with differentiated thyroid carcinoma (DTC). The positive results support a planned new indication submission to China&#039;s Center for Drug Evaluation (CDE), expanding beyond Zesuning&#039;s current approved use as a diagnostic adjunct.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64705\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy\" \/>\n<meta property=\"og:description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its Phase III clinical trial of Zesuning (recombinant human thyrotropin \u03b2) has met the prespecified primary endpoint for postoperative radioactive iodine remnant ablation in patients with differentiated thyroid carcinoma (DTC). The positive results support a planned new indication submission to China&#039;s Center for Drug Evaluation (CDE), expanding beyond Zesuning&#039;s current approved use as a diagnostic adjunct.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64705\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-08T06:14:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-08T06:14:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64705#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64705\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy\",\"datePublished\":\"2026-05-08T06:14:35+00:00\",\"dateModified\":\"2026-05-08T06:14:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64705\"},\"wordCount\":500,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"SHA: 688266\",\"Zelgen Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64705#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64705\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64705\",\"name\":\"Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-08T06:14:35+00:00\",\"dateModified\":\"2026-05-08T06:14:36+00:00\",\"description\":\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its Phase III clinical trial of Zesuning (recombinant human thyrotropin \u03b2) has met the prespecified primary endpoint for postoperative radioactive iodine remnant ablation in patients with differentiated thyroid carcinoma (DTC). The positive results support a planned new indication submission to China's Center for Drug Evaluation (CDE), expanding beyond Zesuning's current approved use as a diagnostic adjunct.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64705#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64705\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64705#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its Phase III clinical trial of Zesuning (recombinant human thyrotropin \u03b2) has met the prespecified primary endpoint for postoperative radioactive iodine remnant ablation in patients with differentiated thyroid carcinoma (DTC). The positive results support a planned new indication submission to China's Center for Drug Evaluation (CDE), expanding beyond Zesuning's current approved use as a diagnostic adjunct.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64705","og_locale":"en_US","og_type":"article","og_title":"Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy","og_description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its Phase III clinical trial of Zesuning (recombinant human thyrotropin \u03b2) has met the prespecified primary endpoint for postoperative radioactive iodine remnant ablation in patients with differentiated thyroid carcinoma (DTC). The positive results support a planned new indication submission to China's Center for Drug Evaluation (CDE), expanding beyond Zesuning's current approved use as a diagnostic adjunct.","og_url":"https:\/\/flcube.com\/?p=64705","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-08T06:14:35+00:00","article_modified_time":"2026-05-08T06:14:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64705#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64705"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy","datePublished":"2026-05-08T06:14:35+00:00","dateModified":"2026-05-08T06:14:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64705"},"wordCount":500,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","SHA: 688266","Zelgen Biopharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64705#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64705","url":"https:\/\/flcube.com\/?p=64705","name":"Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-08T06:14:35+00:00","dateModified":"2026-05-08T06:14:36+00:00","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its Phase III clinical trial of Zesuning (recombinant human thyrotropin \u03b2) has met the prespecified primary endpoint for postoperative radioactive iodine remnant ablation in patients with differentiated thyroid carcinoma (DTC). The positive results support a planned new indication submission to China's Center for Drug Evaluation (CDE), expanding beyond Zesuning's current approved use as a diagnostic adjunct.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64705#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64705"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64705#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Suzhou Zelgen Biopharmaceuticals Achieves Primary Endpoint in Phase III Trial for Zesuning in Thyroid Cancer Ablation Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64705"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64705\/revisions"}],"predecessor-version":[{"id":64708,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64705\/revisions\/64708"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64705"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64705"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}